359 related articles for article (PubMed ID: 19960344)
21. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV
Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
[TBL] [Abstract][Full Text] [Related]
22. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
[TBL] [Abstract][Full Text] [Related]
23. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.
Liu B; Wei J; Zou Z; Qian X; Nakamura T; Zhang W; Ding Y; Feng J; Yu L
Eur J Hum Genet; 2007 Oct; 15(10):1049-53. PubMed ID: 17593927
[TBL] [Abstract][Full Text] [Related]
24. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients.
Hwang IG; Jang JS; Do JH; Kang JH; Lee GW; Oh SY; Kwon HC; Jun HJ; Lim HY; Lee S; Chi KC; Lee SJ
Cancer Chemother Pharmacol; 2011 Oct; 68(4):935-44. PubMed ID: 21298384
[TBL] [Abstract][Full Text] [Related]
25. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
[TBL] [Abstract][Full Text] [Related]
26. Prediction of genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 in the survival of colorectal cancer receiving chemotherapy in the Chinese population.
Liu Y; Chen H; Chen L; Hu C
Hepatogastroenterology; 2012 Jun; 59(116):977-80. PubMed ID: 22580644
[TBL] [Abstract][Full Text] [Related]
27. Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients.
Zhang L; Zhao J; Yu B; Song X; Sun G; Han L; Wang L; Dong S
Cancer Genet; 2017 Dec; 218-219():51-57. PubMed ID: 29153096
[TBL] [Abstract][Full Text] [Related]
28. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Huang ZH; Hua D; Li LH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
[TBL] [Abstract][Full Text] [Related]
29. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
Cho YB; Chung HJ; Lee WY; Choi SH; Kim HC; Yun SH; Chun HK
Anticancer Res; 2011 Nov; 31(11):3843-9. PubMed ID: 22110208
[TBL] [Abstract][Full Text] [Related]
30. [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
Liang J; Li QF; Yao RY; Lü HY; Jiang J; Sun YY; Song SA; Jiang T
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):515-9. PubMed ID: 21029695
[TBL] [Abstract][Full Text] [Related]
31. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
[TBL] [Abstract][Full Text] [Related]
32. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
33. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer.
Chung HH; Kim MK; Kim JW; Park NH; Song YS; Kang SB; Lee HP
Gynecol Oncol; 2006 Dec; 103(3):1031-7. PubMed ID: 16875718
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
Goekkurt E; Al-Batran SE; Hartmann JT; Mogck U; Schuch G; Kramer M; Jaeger E; Bokemeyer C; Ehninger G; Stoehlmacher J
J Clin Oncol; 2009 Jun; 27(17):2863-73. PubMed ID: 19332728
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
[TBL] [Abstract][Full Text] [Related]
36. Polymorphisms of ERCC1 and XRCC1 predict the overall survival of advanced gastric cancer patients receiving oxaliplatin-based chemotherapy.
Zhang L; Yao R; Fang S; Wang X; Li X
Int J Clin Exp Med; 2015; 8(10):18375-82. PubMed ID: 26770441
[TBL] [Abstract][Full Text] [Related]
37. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
Stocker G; Ott K; Henningsen N; Becker K; Hapfelmeier A; Lordick F; Hois S; Plaschke S; Höfler H; Keller G
Eur J Cancer; 2009 Dec; 45(18):3326-35. PubMed ID: 19822419
[TBL] [Abstract][Full Text] [Related]
38. XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.
Ye F; Liu Z; Tan A; Liao M; Mo Z; Yang X
Cancer Chemother Pharmacol; 2013 Mar; 71(3):733-40. PubMed ID: 23299794
[TBL] [Abstract][Full Text] [Related]
39. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.
Huang ZH; Hua D; Du X; Li LH; Mao Y; Liu ZH; Song MX; Zhou XK
World J Gastroenterol; 2008 Nov; 14(41):6401-7. PubMed ID: 19009659
[TBL] [Abstract][Full Text] [Related]
40. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis.
Yu D; Zhang X; Liu J; Yuan P; Tan W; Guo Y; Sun T; Zhao D; Yang M; Liu J; Xu B; Lin D
Clin Cancer Res; 2008 May; 14(9):2878-86. PubMed ID: 18451256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]